Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
07 7월 2021 - 9:00PM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on
developing FT218, an investigational, once-nightly formulation of
sodium oxybate for treating excessive daytime sleepiness and
cataplexy in adults with narcolepsy, announced today that Greg
Divis, Chief Executive Officer of Avadel, will participate in a
fireside chat on Wednesday, July 14 at 11:00 a.m. ET.
A live webcast of this event, as well as an archived recording,
will be available on Avadel’s Investor Relations website,
www.investors.avadel.com, for 90 days following the conference.
About Avadel Pharmaceuticals plcAvadel
Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company
primarily focused on the development and FDA approval of FT218, an
investigational, once-nightly, extended-release formulation of
sodium oxybate designed to treat excessive daytime sleepiness and
cataplexy in adults with narcolepsy. For more information, please
visit www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc. Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Nicole Raisch GoelzReal
Chemistryngoelz@realchemistry.com(408) 568-4292
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024